Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual...
October 23 2019 - 8:00AM
Business Wire
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX),
a clinical-stage biotechnology company developing novel cell
therapies for unmet medical needs, announced today that Igor
Nasonkin, Ph.D., Principal Investigator and Director of R&D,
served as a co-Chair of the Neural Differentiation,
Transplantation, and Regeneration Nanosymposium, in addition to
presenting data on the Company’s Vision Restoration Program at
Neuroscience 2019, the Society for Neuroscience’s 49th Annual
Scientific Meeting. The presentation, entitled “Transplantation of
human embryonic stem cell derived retinal sheets improves vision in
immunodeficient rats with retinal degeneration,” was presented as
part of the Neural Differentiation, Transplantation and
Regeneration Session on Wednesday, October 23rd, 2019 at 8:00 am
Eastern Time in room S505 (Session #626).
The preclinical data presented provided evidence that retinal
tissue produced in Lineage’s laboratory from a human pluripotent
stem cell line was able to engraft tumor-free in rat models used to
study severe retinal degeneration, survived for six months or
longer in the subretinal space, and importantly, showed evidence of
functional improvement. Moreover, the implanted retinal tissue
produced many photoreceptors carrying mature markers including
rhodopsin, established close contact with the retinal pigment
epithelium (RPE) layer, and developed many synaptic boutons
reaching the inner nuclear layers and ganglion cell layer.
Rhodopsin is a biological pigment found in the rods of the retina
and is extremely sensitive to light, thus enabling vision in
low-light conditions. Synaptic boutons are typically the sites
where synapses with other neurons are found, and neurotransmitters
are stored here to communicate with other neurons. This work was
done in collaboration with the University of California, Irvine
(Magdalene J. Seiler, Ph.D., co-PI).
The Vision Restoration Program is a collaborative effort led by
Lineage’s Principal Investigator Igor O. Nasonkin Ph.D., Director
of Research & Development, with Simon Petersen-Jones, DVET MED,
PHD, DECVO, Professor and Donald R. Meyers and William E. Dunlap
Endowed Chair in Canine Health at Michigan State University, and
Magdalene J. Seiler, Ph.D., Associate Professor, Department of
Physical Medicine & Rehabilitation, Department of
Ophthalmology, Sue and Bill Gross Stem Cell Research Center at the
University of California, Irvine. The Vision Restoration Program is
distinct from OpRegen®, the Company’s clinical-stage cell therapy
program which features the sub-retinal delivery of retinal pigment
epithelium cells for the treatment of dry age-related macular
degeneration (dry-AMD).
Guided by its mission and its values, the vision of the Society
for Neuroscience (SfN) is to advance breakthrough discoveries in
neuroscience and promote innovative translation of scientific
advances to improve the health of people everywhere. The SfN’s 49th
annual meeting is the premier venue for neuroscientists to present
emerging science, learn from experts, forge collaborations with
peers, explore new tools and technologies, and advance careers. For
more information, please visit
https://www.sfn.org/Meetings/Neuroscience-2019 or follow the SfN on
Twitter @SfNtweets.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology
company developing novel cell therapies for unmet medical needs.
Lineage’s programs are based on its proprietary cell-based therapy
platform and associated development and manufacturing capabilities.
With this platform Lineage develops and manufactures specialized,
terminally-differentiated human cells from its pluripotent and
progenitor cell starting materials. These differentiated cells are
developed either to replace or support cells that are dysfunctional
or absent due to degenerative disease or traumatic injury or
administered as a means of helping the body mount an effective
immune response to cancer. Lineage’s clinical assets include (i)
OpRegen®, a retinal pigment epithelium transplant therapy in Phase
I/IIa development for the treatment of dry age-related macular
degeneration, a leading cause of blindness in the developed world;
(ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase
I/IIa development for the treatment of acute spinal cord injuries;
and (iii) VAC2, an allogeneic cancer immunotherapy of
antigen-presenting dendritic cells currently in Phase I development
for the treatment of non-small cell lung cancer. Lineage is also
evaluating potential partnership opportunities for Renevia®, a
facial aesthetics product that was recently granted a Conformité
Européenne (CE) Mark. For more information, please visit
www.lineagecell.com or follow the Company on Twitter
@LineageCell.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191023005113/en/
Lineage Cell Therapeutics, Inc. IR Ioana C. Hone
(ir@lineagecell.com) (510) 871-4188
Solebury Trout IR Gitanjali Jain Ogawa
(Gogawa@troutgroup.com) (646) 378-2949
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lineage Cell Therapeutics (AMEX:LCTX)
Historical Stock Chart
From Apr 2023 to Apr 2024